References
- Ilonen J, Lempainen J, Veijola R. The heterogeneous pathogenesis of type 1 diabetes mellitus. Nat Rev Endocrinol [Internet]. 2019 [cited 2023 Sep 27];15:635–650. Available from: https://pubmed.ncbi.nlm.nih.gov/31534209/
- Insel RA, Dunne JL, Atkinson MA, et al. Staging presymptomatic type 1 diabetes: a scientific statement of JDRF, the endocrine society, and the American diabetes association. Diabetes Care [Internet]. 2015 [cited 2023 Dec 1];38(10):1964–1974. Available from: https://pubmed.ncbi.nlm.nih.gov/26404926/
- Rawshani A, Rawshani A, Franzén S, et al. Mortality and cardiovascular disease in type 1 and type 2 diabetes. N Engl J Med [Internet]. 2017 [cited 2023 Dec 1];376(15):1407–1418. Available from: https://pubmed.ncbi.nlm.nih.gov/28402770/
- Herold KC, Bundy BN, Long SA, et al. An anti-CD3 antibody, teplizumab, in relatives at risk for type 1 diabetes. N Engl J Med. 2019;381(7):603–613. doi: 10.1056/NEJMoa1902226.
- Ding J-T, Yang K-P, Lin K-L, et al. Mechanisms and therapeutic strategies of immune checkpoint molecules and regulators in type 1 diabetes. Front Endocrinol (Lausanne) [Internet]. 2023 [cited 2023 Aug 30];13. Available from: https://pubmed.ncbi.nlm.nih.gov/36704045/
- Franzin R, Netti GS, Spadaccino F, et al. The Use of Immune Checkpoint Inhibitors in Oncology and the Occurrence of AKI: where Do We Stand? Front Immunol [Internet]. 2020 [cited 2023 Aug 30];11. Available from: https://pubmed.ncbi.nlm.nih.gov/33162990/
- Edner NM, Carlesso G, Rush JS, et al. Targeting co-stimulatory molecules in autoimmune disease. Nat Rev Drug Discov [Internet]. 2020 [cited 2023 Aug 29];19:860–883.
- Madden K, Kasler MK. Immune Checkpoint Inhibitors in Lung Cancer and Melanoma. Semin Oncol Nurs [Internet]. 2019 [cited 2023 Sep 27];35:150932. Available from: https://pubmed.ncbi.nlm.nih.gov/31561846/
- Kotwal A, Haddox C, Block M, et al. Immune checkpoint inhibitors: an emerging cause of insulin-dependent diabetes. BMJ Open Diabetes Res Care. [Internet]. 2019 [cited 2023 Aug 29];7(1):e000591. Available from: https://pubmed.ncbi.nlm.nih.gov/30899528/
- Shimada K, Yamamoto H, Nakatani E, et al. Real-world evidence of the incidence of and risk factors for type 1 diabetes mellitus and hypothyroidism as immune-related adverse events associated with programmed cell death-1 inhibitors. Endocr Pract [Internet]. 2021 [cited 2023 Aug 29];27(6):586–593. Available from: https://pubmed.ncbi.nlm.nih.gov/34057406/
- Danke NA, Koelle DM, Yee C, et al. Autoreactive T cells in healthy individuals. J Immunol [Internet]. 2004 [cited 2023 Aug 29];172(10):5967–5972. Available from: https://pubmed.ncbi.nlm.nih.gov/15128778/
- James EAA, Pietropaolo M, Mamula MJJ. Immune recognition of β-cells: neoepitopes as key players in the loss of tolerance. Diabetes. 2018;67(6):1035–1042.
- Noble JA, Valdes AM, Varney MD, et al. Type 1 Diabetes Genetics Consortium. HLA class I and genetic susceptibility to type 1 diabetes: results from the Type 1 Diabetes Genetics Consortium. Diabetes. 2010 Nov;59(11):2972–2979. doi: 10.2337/db10-0699
- Petrone A, Bugawan TL, Mesturino CA, et al. The distribution of HLA class II susceptible/protective haplotypes could partially explain the low incidence of type 1 diabetes in continental Italy (Lazio region). Tissue Antigens. 2001Dec;58(6):385–394. doi: 10.1034/j.1399-0039.2001.580607.x
- Von Boehmer H. Central tolerance: essential for preventing autoimmune disease? Eur J Immunol [Internet]. 2009 [cited 2023 Aug 29];39:2313–2316. Available from: https://pubmed.ncbi.nlm.nih.gov/19714571/
- Kumar P, Saini S, Khan S, et al. Restoring self-tolerance in autoimmune diseases by enhancing regulatory T-cells. Cell Immunol [Internet]. 2019 [cited 2023 Aug 29];339:41–49. Available from: https://pubmed.ncbi.nlm.nih.gov/30482489/
- Pietropaolo M, Towns R, Eisenbarth GS. Humoral autoimmunity in type 1 diabetes: prediction, significance, and detection of distinct disease subtypes. Cold Spring Harb Perspect Med [Internet]. 2012 [cited 2023 Aug 29];2:a012831–a012831. Available from: https://pubmed.ncbi.nlm.nih.gov/23028135/
- Kyewski B, Klein L. A central role for central tolerance. Annu Rev Immunol [Internet]. 2006 [cited 2023 Aug 29];24:571–606. Available from: https://pubmed.ncbi.nlm.nih.gov/16551260/
- Pugliese A, Zeller M, Fernandez A, et al. The insulin gene is transcribed in the human thymus and transcription levels correlated with allelic variation at the INS VNTR-IDDM2 susceptibility locus for type 1 diabetes. Nat Genet [Internet]. 1997 [cited 2023 Aug 29];15(3):293–297. Available from: https://pubmed.ncbi.nlm.nih.gov/9054945/
- Vafiadis P, Bennett ST, Todd JA, et al. Insulin expression in human thymus is modulated by INS VNTR alleles at the IDDM2 locus. Nat Genet. 1997Mar;15(3):289–292. doi: 10.1038/ng0397-289.
- Vafiadis P, Ounissi-Benkalha H, Palumbo M, et al. Class III alleles of the variable number of tandem repeat insulin polymorphism associated with silencing of thymic insulin predispose to type 1 diabetes. J Clin Endocrinol Metab [Internet]. 2001 [cited 2023 Aug 29];86(8):3705–3710. Available from: https://pubmed.ncbi.nlm.nih.gov/11502799/
- Doyle HA, Mamula MJ. Autoantigenesis: the evolution of protein modifications in autoimmune disease. Curr Opin Immunol [Internet]. 2012 [cited 2023 Aug 29];24:112–118. Available from: https://pubmed.ncbi.nlm.nih.gov/22209691/
- Mohan JF, Petzold SJ, Unanue ER. Register shifting of an insulin peptide-MHC complex allows diabetogenic T cells to escape thymic deletion. J Exp Med [Internet]. 2011 [cited 2023 Aug 29];208:2375–2383. Available from: https://pubmed.ncbi.nlm.nih.gov/22065673/
- Strollo R, Vinci C, Napoli N, et al. Antibodies to oxidized insulin improve prediction of type 1 diabetes in children with positive standard islet autoantibodies. Diabetes Metab Res Rev. 2019;35(4):e3132. doi: 10.1002/dmrr.3132.
- Schneider A, Rieck M, Sanda S, et al. The effector T cells of diabetic subjects are resistant to regulation via CD4+ FOXP3+ regulatory T cells. J Immunol [Internet]. 2008 cited 2023 Aug 29;181(10):7350–7355. Available from: https://pubmed.ncbi.nlm.nih.gov/18981158/
- Buckner JH. Mechanisms of impaired regulation by CD4(+)CD25(+)FOXP3(+) regulatory T cells in human autoimmune diseases. Nat Rev Immunol [Internet]. 2010 [cited 2023 Aug 29];10:849–859. Available from: https://pubmed.ncbi.nlm.nih.gov/21107346/
- Ferraro A, Socci C, Stabilini A, et al. Expansion of Th17 cells and functional defects in T regulatory cells are key features of the pancreatic lymph nodes in patients with type 1 diabetes. Diabetes [Internet]. 2011 [cited 2023 Aug 29];60(11):2903–2913. Available from: https://pubmed.ncbi.nlm.nih.gov/21896932/
- Gallagher GR, Brehm MA, Finberg RW, et al. Viral infection of engrafted human islets leads to diabetes. Diabetes [Internet]. 2015 [cited 2023 Aug 29];64(4):1358–1369. Available from: https://pubmed.ncbi.nlm.nih.gov/25392246/
- Ferreira RC, Guo H, Coulson RMR, et al. A type I Interferon transcriptional signature precedes autoimmunity in children genetically at risk for type 1 diabetes. Diabetes [Internet]. 2014 [cited 2023 Jun 2];63(7):2538–2550. Available from: https://pubmed.ncbi.nlm.nih.gov/24561305/
- Marroqui L, Dos Santos RS, Op de Beeck A, et al. Interferon-α mediates human beta cell HLA class I overexpression, endoplasmic reticulum stress and apoptosis, three hallmarks of early human type 1 diabetes. Diabetologia [Internet]. 2017 [cited 2023 Jun 2];60(4):656–667. Available from: https://pubmed.ncbi.nlm.nih.gov/28062922/
- De Beeck AO, Eizirik DL. Viral infections in type 1 diabetes mellitus–why the β cells? Nat Rev Endocrinol [Internet]. 2016 [cited 2023 Aug 29];12:263–273. Available from: https://pubmed.ncbi.nlm.nih.gov/27020257/
- Eizirik DL, Miani M, Cardozo AK. Signalling danger: endoplasmic reticulum stress and the unfolded protein response in pancreatic islet inflammation. Diabetologia [Internet]. 2013 [cited 2023 Aug 29];56:234–241. Available from: https://pubmed.ncbi.nlm.nih.gov/23132339/
- Pane JA, Coulson BS. Lessons from the mouse: potential contribution of bystander lymphocyte activation by viruses to human type 1 diabetes. Diabetologia [Internet]. 2015 [cited 2023 Aug 29];58:1149–1159. Available from: https://pubmed.ncbi.nlm.nih.gov/25794781/
- Coppieters KT, Wiberg A, von Herrath MG. Viral infections and molecular mimicry in type 1 diabetes. APMIS [Internet]. 2012 [cited 2023 Aug 29];120:941–949. Available from: https://pubmed.ncbi.nlm.nih.gov/23051179/
- Wiedeman AE, Speake C, Long SA. The many faces of islet antigen-specific CD8 T cells: clues to clinical outcome in type 1 diabetes. Immunol Cell Biol [Internet]. 2021 [cited 2023 Aug 29];99:475–485. Available from: https://pubmed.ncbi.nlm.nih.gov/33483981/
- Zakharov PN, Hu H, Wan X, et al. Single-cell RNA sequencing of murine islets shows high cellular complexity at all stages of autoimmune diabetes. J Exp Med [Internet]. 2020 [cited 2023 Aug 29];217(6). Available from: https://pubmed.ncbi.nlm.nih.gov/32251514/
- Babon JAB, Denicola ME, Blodgett DM, et al. Analysis of self-antigen specificity of islet-infiltrating T cells from human donors with type 1 diabetes. Nat Med [Internet]. 2016 [cited 2023 Aug 29];22(12):1482–1487. Available from: https://pubmed.ncbi.nlm.nih.gov/27798614/
- Nakayasu ES, Qian WJ, Evans-Molina C, et al. The role of proteomics in assessing beta-cell dysfunction and death in type 1 diabetes. Expert Rev Proteomics [Internet]. 2019 [cited 2023 Aug 29];16:569–582. Available from: https://pubmed.ncbi.nlm.nih.gov/31232620/
- Kronenberg D, Knight RR, Estorninho M, et al. Circulating preproinsulin signal peptide-specific CD8 T cells restricted by the susceptibility molecule HLA-A24 are expanded at onset of type 1 diabetes and kill β-cells. Diabetes [Internet]. 2012 [cited 2023 Aug 30];61(7):1752–1759. Available from: https://pubmed.ncbi.nlm.nih.gov/22522618/
- Chow IT, Yang J, Gates TJ, et al. Assessment of CD4+ T cell responses to glutamic acid decarboxylase 65 using DQ8 tetramers reveals a pathogenic role of GAD65 121-140 and GAD65 250-266 in T1D development. PLoS One [Internet]. 2014 [cited 2023 Aug 30];9(11):e112882. Available from: https://pubmed.ncbi.nlm.nih.gov/25405480/
- Hawkes CJ, Schloot NC, Marks J, et al. T-cell lines reactive to an immunodominant epitope of the tyrosine phosphatase-like autoantigen IA-2 in type 1 diabetes. Diabetes [Internet]. 2000 [cited 2023 Aug 30];49(3):356–366. Available from: https://pubmed.ncbi.nlm.nih.gov/10868956/
- Yang J, Danke NA, Berger D, et al. Islet-specific glucose-6-phosphatase catalytic subunit-related protein-reactive CD4+ T cells in human subjects. J Immunol [Internet]. 2006 [cited 2023 Aug 30];176(5):2781–2789. Available from: https://pubmed.ncbi.nlm.nih.gov/16493034/
- Wenzlau JM, Juhl K, Yu L, et al. The cation efflux transporter ZnT8 (Slc30A8) is a major autoantigen in human type 1 diabetes. Proc Natl Acad Sci USA. [Internet]. 2007 [cited 2023 Aug 30];104(43):17040–17045. Available from: https://pubmed.ncbi.nlm.nih.gov/17942684/
- Sun L, Xi S, He G, et al. Two to Tango: dialogue between Adaptive and Innate Immunity in Type 1 Diabetes. J Diabetes Res [Internet]. 2020 [cited 2023 Aug 29];2020. Available from: https://pubmed.ncbi.nlm.nih.gov/32802890/.
- Zhang Y, Zheng J. Functions of Immune Checkpoint Molecules Beyond Immune Evasion. Adv Exp Med Biol [Internet]. 2020 [cited 2023 Aug 30];1248:201–226.
- Au KM, Medik Y, Ke Q, et al. Immune checkpoint-bioengineered beta cell vaccine reverses early-onset type 1 diabetes. Adv Mater [Internet]. 2021 [cited 2023 Aug 30];33(25). Available from: https://pubmed.ncbi.nlm.nih.gov/33963786/
- Trabattoni D, Saresella M, Pacei M, et al. Costimulatory pathways in multiple sclerosis: distinctive expression of PD-1 and PD-L1 in patients with different patterns of disease. J Immunol [Internet]. 2009 [cited 2023 Aug 30];183(8):4984–4993. Available from: https://pubmed.ncbi.nlm.nih.gov/19794071/
- Ben NM, Tezza S, D’Addio F, et al. PD-L1 genetic overexpression or pharmacological restoration in hematopoietic stem and progenitor cells reverses autoimmune diabetes. Sci Transl Med [Internet]. 2017 [cited 2023 Aug 30];9. Available from: https://pubmed.ncbi.nlm.nih.gov/29141886/
- Dahlén E, Hedlund G, Dawe K. Low CD86 expression in the nonobese diabetic mouse results in the impairment of both T cell activation and CTLA-4 up-regulation. J Immunol [Internet]. 2000 [cited 2023 Aug 30];164:2444–2456. Available from: https://pubmed.ncbi.nlm.nih.gov/10679081/
- Kanzaki M, Wada J, Sugiyama K, et al. Galectin-9 and T cell immunoglobulin mucin-3 pathway is a therapeutic target for type 1 diabetes. Endocrinology. Internet]. 2012 [cited 2023 Aug 30];153(2):612–620. Available from: https://pubmed.ncbi.nlm.nih.gov/22186414/
- Ansari MJI, Salama AD, Chitnis T, et al. The programmed death-1 (PD-1) pathway regulates autoimmune diabetes in nonobese diabetic (NOD) mice. J Exp Med [Internet]. 2003 [cited 2023 Aug 30];198(1):63–69. Available from: https://pubmed.ncbi.nlm.nih.gov/12847137/
- Hossen MM, Ma Y, Yin Z, et al. Current understanding of CTLA-4: from mechanism to autoimmune diseases. Front Immunol [Internet]. 2023 [cited 2023 Aug 30];14. Available from: https://pubmed.ncbi.nlm.nih.gov/37497212/
- Karandikar NJ, Vanderlugt CL, Walunas TL, et al. CTLA-4: a negative regulator of autoimmune disease. J Exp Med [Internet]. 1996 [cited 2023 Aug 30];184(2):783–788. Available from: https://pubmed.ncbi.nlm.nih.gov/8760834/
- Thompson CB, Allison JP. The emerging role of CTLA-4 as an immune attenuator. Immunity [Internet]. 1997 [cited 2023 Aug 30];7:445–450. Available from: https://pubmed.ncbi.nlm.nih.gov/9354465/
- Van Coillie S, Wiernicki B, Xu J. Molecular and Cellular Functions of CTLA-4. Adv Exp Med Biol [Internet]. 2020 [cited 2023 Aug 30];1248:7–32. Available from: https://pubmed.ncbi.nlm.nih.gov/32185705/
- Rachid O, Osman A, Abdi R, et al. CTLA4-Ig (Abatacept): a promising investigational drug for use in type 1 diabetes. Expert Opin Investig Drugs [Internet]. 2020 [cited 2023 Aug 30];29(3):221–236. Available from: https://pubmed.ncbi.nlm.nih.gov/32031422/
- Teft WA, Kirchhof MG, Madrenas J. A molecular perspective of CTLA-4 function. Annu Rev Immunol [Internet]. 2006 [cited 2023 Aug 30];24:65–97. Available from: https://pubmed.ncbi.nlm.nih.gov/16551244/
- Qureshi OS, Zheng Y, Nakamura K, et al. Trans-endocytosis of CD80 and CD86: a molecular basis for the cell-extrinsic function of CTLA-4. Science [Internet]. 2011 [cited 2023 Aug 30];332(6029):600–603. Available from: https://pubmed.ncbi.nlm.nih.gov/21474713/
- Mellor AL, Munn DH. IDO expression by dendritic cells: tolerance and tryptophan catabolism. Nat Rev Immunol [Internet]. 2004 [cited 2023 Aug 30];4:762–774. Available from: https://pubmed.ncbi.nlm.nih.gov/15459668/
- Alissafi T, Banos A, Boon L, et al. Tregs restrain dendritic cell autophagy to ameliorate autoimmunity. J Clin Invest [Internet]. 2017 [cited 2023 Aug 30];127(7):2789–2804. Available from: https://pubmed.ncbi.nlm.nih.gov/28581446/
- Hosseini A, Gharibi T, Marofi F, et al. CTLA-4: from mechanism to autoimmune therapy. Int Immunopharmacol [Internet]. 2020 [cited 2023 Aug 30];80. Available from: https://pubmed.ncbi.nlm.nih.gov/32007707/
- Qi X, Wang J, Xu Z, et al. Relationship of CTLA-4 gene to latent autoimmune diabetes in adults and Type 2 diabetes: a population-based case–control study. Diabetes Manag. 2014;4(2):131–139. doi: 10.2217/dmt.13.70.
- Nisticò L, Buzzetti R, Pritchard LE, et al. The CTLA-4 gene region of chromosome 2q33 is linked to, and associated with, type 1 diabetes. Belgian Diabetes Registry. Hum Mol Genet. 1996;5(7):1075–1080. doi: 10.1093/hmg/5.7.1075.
- You S, Alyanakian MA, Segovia B, et al. Immunoregulatory pathways controlling progression of autoimmunity in NOD mice. Ann N Y Acad Sci [Internet]. 2008 [cited 2023 Aug 30];1150(1):300–310. Available from: https://pubmed.ncbi.nlm.nih.gov/19120317/
- Zóka A, Barna G, Somogyi A, et al. Extension of the CD4 + Foxp3 + CD25 −/low regulatory T-cell subpopulation in type 1 diabetes mellitus. Autoimmunity [Internet]. 2015 [cited 2023 Aug 30];48(5):289–297. Available from: https://pubmed.ncbi.nlm.nih.gov/25523632/
- Orban T, Beam CA, Xu P, et al. Reduction in CD4 central memory T-cell subset in costimulation modulator Abatacept-treated patients with recent-onset type 1 diabetes is associated with slower C-peptide decline. Diabetes [Internet]. 2014 [cited 2023 Dec 1];63(10):3449–3457. Available from: https://pubmed.ncbi.nlm.nih.gov/24834977/
- Burke KP, Patterson DG, Liang D, et al. Immune checkpoint receptors in autoimmunity. Curr Opin Immunol [Internet]. 2023 [cited 2023 Aug 29];80:102283. Available from: https://pubmed.ncbi.nlm.nih.gov/36709596/
- Grebinoski S, Zhang Q, Cillo AR, et al. Autoreactive CD8+ T cells are restrained by an exhaustion-like program that is maintained by LAG3. Nat Immunol [Internet]. 2022 [cited 2023 Aug 29];23(6):868–877. Available from: https://pubmed.ncbi.nlm.nih.gov/35618829/
- Klocke K, Sakaguchi S, Holmdahl R, et al. Induction of autoimmune disease by deletion of CTLA-4 in mice in adulthood. Proc Natl Acad Sci USA [Internet]. 2016 [cited 2023 Aug 29];113(17). Available from: https://pubmed.ncbi.nlm.nih.gov/27071130/
- Rezayi M, Hosseini A. Structure of PD1 and its mechanism in the treatment of autoimmune diseases. Cell Biochem Funct [Internet]. 2023 [cited 2023 Aug 30]. Available from: https://pubmed.ncbi.nlm.nih.gov/37475518/.
- Wang CJ, Chou FC, Chu CH, et al. Protective role of programmed death 1 ligand 1 (PD-L1)in nonobese diabetic mice: the paradox in transgenic models. Diabetes [Internet]. 2008 [cited 2023 Aug 30];57(7):1861–1869. Available from: https://pubmed.ncbi.nlm.nih.gov/18420489/
- Kadri N, Korpos E, Gupta S, et al. CD4+ type ii nkt cells mediate ICOS and programmed Death-1–Dependent regulation of type 1 diabetes. J Immunol [Internet]. 2012 [cited 2023 Aug 30];188(7):3138–3149. Available from: https://pubmed.ncbi.nlm.nih.gov/22371394/
- Paterson AM, Brown KE, Keir ME, et al. The programmed death-1 ligand 1:B7-1 pathway restrains diabetogenic effector T cells in vivo. J Immunol [Internet]. 2011 [cited 2023 Aug 30];187(3):1097–1105. Available from: https://pubmed.ncbi.nlm.nih.gov/21697456/
- Zhao P, Wang P, Dong S, et al. Depletion of PD-1-positive cells ameliorates autoimmune disease. Nat Biomed Eng [Internet]. 2019 cited 2023 Aug 30;3(4):292–305. Available from: https://pubmed.ncbi.nlm.nih.gov/30952980/
- Zhao C, Tella SH, Del RJ, et al. Anti-PD-L1 Treatment Induced Central Diabetes Insipidus. J Clin Endocrinol Metab [Internet]. 2018 [cited 2023 Aug 30];103(2):365–369. Available from: https://pubmed.ncbi.nlm.nih.gov/29220526/
- Au KM, Tisch R, Wang AZ. In vivo bioengineering of beta cells with immune checkpoint ligand as a treatment for early-onset type 1 diabetes mellitus. ACS Nano [Internet]. 2021 [cited 2023 Aug 30];15:19990–20002. Available from: https://pubmed.ncbi.nlm.nih.gov/34843648/
- Wang P, Yoo B, Yang J, et al. GLP-1R-targeting magnetic nanoparticles for pancreatic islet imaging. Diabetes [Internet]. 2014 [cited 2023 Aug 30];63(5):1465–1474. Available from: https://pubmed.ncbi.nlm.nih.gov/24458362/
- Tuttle J, Drescher E, Simón-Campos JA, et al. A phase 2 trial of peresolimab for adults with rheumatoid arthritis. N Engl J Med. 2023;388(20):1853–1862. doi: 10.1056/NEJMoa2209856.
- Liu Y, Chen H, Chen Z, et al. Novel roles of the time family in immune regulation and autoimmune diseases. Front Immunol [Internet]. 2021 [cited 2023 Aug 30];12. Available from: https://pubmed.ncbi.nlm.nih.gov/34603337/
- Das M, Zhu C, Kuchroo VK. Tim-3 and its role in regulating anti-tumor immunity. Immunol Rev [Internet]. 2017 [cited 2023 Aug 30];276:97–111. Available from: https://pubmed.ncbi.nlm.nih.gov/28258697/
- Zhang Q, Chikina M, Szymczak-Workman AL, et al. LAG3 limits regulatory T cell proliferation and function in autoimmune diabetes. Sci Immunol [Internet]. 2017 [cited 2023 Aug 30];2(9). Available from: https://pubmed.ncbi.nlm.nih.gov/28783703/
- Maruhashi T, Sugiura D, I Mi O, et al. Binding of LAG-3 to stable peptide-MHC class II limits T cell function and suppresses autoimmunity and anti-cancer immunity. Immunity [Internet]. 2022 [cited 2023 Aug 30];55(5):912–924.e8. Available from: https://pubmed.ncbi.nlm.nih.gov/35413245/
- Jones BE, Maerz MD, Bahnson HT, et al. Fewer LAG-3+ T cells in relapsing-remitting multiple sclerosis and type 1 diabetes. J Immunol [Internet]. 2022 [cited 2023 Aug 30];208(3):594–602. Available from: https://pubmed.ncbi.nlm.nih.gov/35022272/
- Vazquez-Mateo C, Collins J, Fleury M, et al. Broad induction of immunoregulatory mechanisms after a short course of anti-IL-7Rα antibodies in NOD mice. BMC Immunol [Internet]. 2017 [cited 2023 Aug 30];18(1). Available from: https://pubmed.ncbi.nlm.nih.gov/28356069/
- Ellis J, van Maurik A, Fortunato L, et al. Anti-IL-7 receptor α monoclonal antibody (GSK2618960) in healthy subjects - a randomized, double-blind, placebo-controlled study. Br J Clin Pharmacol [Internet]. 2019 [cited 2023 Dec 1];85(2):304–315. Available from: https://pubmed.ncbi.nlm.nih.gov/30161291/
- Poirier N, Baccelli I, Belarif L, et al. First-in-human study in healthy subjects with the noncytotoxic monoclonal antibody ose-127, a strict antagonist of IL-7Rα. J Immunol [Internet]. 2023 [cited 2023 Dec 1];210(6):753–763. Available from: https://pubmed.ncbi.nlm.nih.gov/36734626/
- Herold KC, Bucktrout SL, Wang X, et al. Immunomodulatory activity of humanized anti-IL-7R monoclonal antibody RN168 in subjects with type 1 diabetes. JCI Insight [Internet]. 2019 [cited 2023 Dec 1];4(24). Available from: https://pubmed.ncbi.nlm.nih.gov/31852846/
- Marro BS, Ware BC, Zak J, et al. Progression of type 1 diabetes from the prediabetic stage is controlled by interferon-α signaling. Proc Natl Acad Sci USA [Internet]. 2017 [cited 2023 Aug 30];114(14):3708–3713. Available from: https://pubmed.ncbi.nlm.nih.gov/28325871/
- Kappos L, O’Connor P, Radue EW, et al. Long-term effects of fingolimod in multiple sclerosis: the randomized FREEDOMS extension trial. Neurology [Internet]. 2015 [cited 2023 Dec 6];84(15):1582–1591. Available from: https://pubmed.ncbi.nlm.nih.gov/25795646/
- Sandborn WJ, Feagan BG, Hanauer S, et al. Long-term efficacy and safety of ozanimod in moderately to severely active ulcerative colitis: results from the open-label extension of the randomized, phase 2 TOUCHSTONE study. J Crohns Colitis [Internet]. 2021 [cited 2023 Dec 6];15(7):1120–1129. Available from: https://pubmed.ncbi.nlm.nih.gov/33438008/
- Feagan BG, Sandborn WJ, Danese S, et al. Ozanimod induction therapy for patients with moderate to severe Crohn’s disease: a single-arm, phase 2, prospective observer-blinded endpoint study. lancet Gastroenterol Hepatol [Internet]. 2020 [cited 2023 Dec 6];5(9):819–828. Available from: https://pubmed.ncbi.nlm.nih.gov/32553149/
- Mbongue JC, Rawson J, Garcia PA, et al. Reversal of new onset type 1 diabetes by oral salmonella-based combination therapy and mediated by regulatory t-cells in nod mice. Front Immunol [Internet]. 2019 [cited 2023 Aug 30];10. Available from: https://pubmed.ncbi.nlm.nih.gov/30863412/
- Quattrin T, Haller MJ, Steck AK, et al. Golimumab and beta-cell function in youth with new-onset type 1 diabetes. N Engl J Med. 2020;383(21):2007–2017. doi: 10.1056/NEJMoa2006136.
- Imai A, Suzuki T, Sugitani A, et al. A novel fully human anti-CD40 monoclonal antibody, 4D11, for kidney transplantation in cynomolgus monkeys. Transplantation [Internet]. 2007 [cited 2023 Aug 30];84(8):1020–1028. Available from: https://pubmed.ncbi.nlm.nih.gov/17989608/
- Mahmoudzadeh A, Pourfathollah AA, Karimi MH, et al. Cd40 knocked down tolerogenic dendritic cells decrease diabetic injury. Iran J Immunol. 2017;14:270–280.
- Vujicic M, Saksida T, Mostarica Stojkovic M, et al. Protective effects of carbonyl iron against multiple low-dose streptozotocin-induced diabetes in rodents. J Cell Physiol [Internet]. 2018 [cited 2023 Aug 30];233:4990–5001.
- Meylan F, Siegel RM. TNF superfamily cytokines in the promotion of Th9 differentiation and immunopathology. Semin Immunopathol [Internet]. 2017 [cited 2023 Aug 30];39:21–28. Available from: https://pubmed.ncbi.nlm.nih.gov/27896636/
- Fu NN, Xie F, Sun ZW, et al. The OX40/OX40L axis regulates t follicular helper cell differentiation: implications for autoimmune diseases. Front Immunol [Internet]. 2021 [cited 2023 Aug 30];12. Available from: https://pubmed.ncbi.nlm.nih.gov/34234777/
- An J, Ding S, Li S, et al. Enhancement of the soluble form of OX40 and OX40L costimulatory molecules but reduction of the membrane form in type 1 diabetes (T1D). J Immunol Res [Internet]. 2019 [cited 2023 Aug 30];2019:1780567. Available from: https://pubmed.ncbi.nlm.nih.gov/31467932/
- Bresson D, Fousteri G, Manenkova Y, et al. Antigen-specific prevention of type 1 diabetes in NOD mice is ameliorated by OX40 agonist treatment. J Autoimmun [Internet]. 2011 [cited 2023 Aug 30];37:342–351.
- Wong HY, Schwarz H. CD137/CD137 ligand signalling regulates the immune balance: a potential target for novel immunotherapy of autoimmune diseases. J Autoimmun [Internet]. 2020 [cited 2023 Aug 30];112:102499. Available from: https://pubmed.ncbi.nlm.nih.gov/32505443/
- Itoh A, Ortiz L, Kachapati K, et al. Soluble CD137 ameliorates acute type 1 diabetes by inducing t cell anergy. Front Immunol [Internet]. 2019 [cited 2023 Aug 30];10. Available from: https://pubmed.ncbi.nlm.nih.gov/31787971/
- Forsberg MH, Ciecko AE, Bednar KJ, et al. CD137 plays both pathogenic and protective roles in type 1 diabetes development in NOD mice. J Immunol [Internet]. 2017 [cited 2023 Aug 30];198(10):3857–3868. Available from: https://pubmed.ncbi.nlm.nih.gov/28363905/
- Sacquin A, Gador M, Fazilleau N. The strength of BCR signaling shapes terminal development of follicular helper T cells in mice. Eur J Immunol [Internet]. 2017 [cited 2023 Aug 30];47:1295–1304. Available from: https://pubmed.ncbi.nlm.nih.gov/28605013/
- Kenefeck R, Wang CJ, Kapadi T, et al. Follicular helper T cell signature in type 1 diabetes. J Clin Invest [Internet]. 2015 [cited 2023 Aug 30];125(1):292–303. Available from: https://pubmed.ncbi.nlm.nih.gov/25485678/
- Gigoux M, Shang J, Pak Y, et al. Inducible costimulator promotes helper T-cell differentiation through phosphoinositide 3-kinase. Proc Natl Acad Sci USA [Internet]. 2009 [cited 2023 Aug 30];106(48):20371–20376. Available from: https://pubmed.ncbi.nlm.nih.gov/19915142/
- Grimbacher B, Hutloff A, Schlesier M, et al. Homozygous loss of ICOS is associated with adult-onset common variable immunodeficiency. Nat Immunol [Internet]. 2003 [cited 2023 Aug 30];4(3):261–268. Available from: https://pubmed.ncbi.nlm.nih.gov/12577056/
- Metz DP, Mohn D, Zhang M, et al. Defining dose-response relationships in the therapeutic blockade of B7RP-1-dependent immune responses. Eur J Pharmacol [Internet]. 2009 [cited 2023 Aug 29];610(1–3):110–118. Available from: https://pubmed.ncbi.nlm.nih.gov/19292985/
- Hu YL, Metz DP, Chung J, et al. B7RP-1 blockade ameliorates autoimmunity through regulation of follicular helper T cells. J Immunol [Internet]. 2009 [cited 2023 Aug 29];182(3):1421–1428. Available from: https://pubmed.ncbi.nlm.nih.gov/19155489/
- Moreland L, Bate G, Kirkpatrick P. Abatacept. Nat Rev Drug Discov. 2006;5(3):185–186.
- Lenschow DJ, Ho SC, Sattar H, et al. Differential effects of anti-B7-1 and anti-B7-2 monoclonal antibody treatment on the development of diabetes in the nonobese diabetic mouse. J Exp Med [Internet]. 1995 [cited 2023 Aug 30];181(3):1145–1155. Available from: https://pubmed.ncbi.nlm.nih.gov/7532678/
- Lenschow DJ, Zeng Y, Thistlethwaite JR, et al. Long-term survival of xenogeneic pancreatic islet grafts induced by CTLA4lg. Science [Internet]. 1992 cited 2023 Aug 30;257(5071):789–792. Available from: https://pubmed.ncbi.nlm.nih.gov/1323143/
- Orban T, Bundy B, Becker DJJ, et al., Co-stimulation modulation with Abatacept in patients with recent-onset type 1 diabetes: a randomised, double-blind, placebo-controlled trial. Lancet. 2011;378(9789):412–419. doi: 10.1016/S0140-6736(11)60886-6.
- Orban T, Bundy B, Becker DJ, et al. Costimulation modulation with Abatacept in patients with recent-onset type 1 diabetes: follow-up 1 year after cessation of treatment. Diabetes Care [Internet]. 2014 [cited 2023 Aug 30];37(4):1069–1075. Available from: https://pubmed.ncbi.nlm.nih.gov/24296850/
- Russell WE, Bundy BN, Anderson MS, et al. Abatacept for delay of type 1 diabetes progression in stage 1 relatives at risk: a randomized, double-masked, controlled trial. Diabetes Care [Internet]. 2023 [cited 2023 Aug 30];46:1005–1013.
- Sayed BA, Kirk AD, Pearson TC, et al. Belatacept. Chapter 21. kidney transplantation–principles pract. 7th ed. Elsevier; 2014. p. 314–319.
- Lombardi Y, François H. Belatacept in kidney transplantation: what are the true benefits? A systematic review. Front Med. 2022;9. doi: 10.3389/fmed.2022.942665
- Lowe MC, Badell IR, Turner AP, et al. Belatacept and sirolimus prolong nonhuman primate islet allograft survival: adverse consequences of concomitant alefacept therapy. Am J Transplant [Internet]. 2013 [cited 2023 Aug 30];13(2):312–319. Available from: https://pubmed.ncbi.nlm.nih.gov/23279640/
- Posselt AM, Szot GL, Frassetto LA, et al. Islet transplantation in type 1 diabetic patients using calcineurin inhibitor-free immunosuppressive protocols based on T-cell adhesion or costimulation blockade. Transplantation [Internet]. 2010 [cited 2023 Aug 30];90(12):1595–1601. Available from: https://pubmed.ncbi.nlm.nih.gov/20978464/
- Maddaloni E, Bolli GB, Frier BM, et al. C-peptide determination in the diagnosis of type of diabetes and its management: a clinical perspective. Diabetes Obes Metab. 2022 Oct;24(10): 1912–1926. doi: 10.1111/dom.14785
- Gregory GA, Robinson TIG, Linklater SE, et al. Global incidence, prevalence, and mortality of type 1 diabetes in 2021 with projection to 2040: a modelling study. Lancet Diabetes Endocrinol. 2022;10(10):741–760. doi: 10.1016/S2213-8587(22)00218-2.
- Buzzetti R, Maddaloni E, Gaglia J, et al. Adult-onset autoimmune diabetes. Nat Rev Dis Prim [Internet]. 2022 [cited 2023 Jun 2];8. Available from: https://pubmed.ncbi.nlm.nih.gov/36138034/
- Maddaloni E, D’Eon S, Hastings S, et al. Bone health in subjects with type 1 diabetes for more than 50 years. Acta Diabetol. 2017;54(5):1–10. doi: 10.1007/s00592-017-0973-2.
- Keenan HA, Maddaloni E. Bone microarchitecture in type 1 diabetes: it is complicated. Curr Osteoporos Rep. 2016;14(6):351–358.
- Leanza G, Maddaloni E, Pitocco D, et al. Risk factors for fragility fractures in type 1 diabetes. Bone. 2019;125:194–199.
- Siddiqui K, Maddaloni E. Editorial: the changing panorama of diabetes outcomes: novel complications and novelties in classical complication. Front Endocrinol (Lausanne). 2022 Jan 13;12:816481. doi: 10.3389/fendo.2021.816481
- Mignogna C, Maddaloni E, D’Onofrio L, et al. Investigational therapies targeting CD3 for prevention and treatment of type 1 diabetes. Expert Opin Investig Drugs. 2021;30(12):1209–1219.
- Battaglia M, Ahmed S, Anderson MS, et al. Introducing the endotype concept to address the challenge of disease heterogeneity in type 1 diabetes. Diabetes Care. 2020;43(1):5–12. doi: 10.2337/dc19-0880.
- Redondo MJ, Morgan NG. Heterogeneity and endotypes in type 1 diabetes mellitus. Nat Rev Endocrinol [Internet]. 2023 [cited 2023 Aug 30];19:542–554. Available from: https://pubmed.ncbi.nlm.nih.gov/37337007/
- Fiorina P, Pozzilli P. Unveiling a novel type 1 diabetes endotype: opportunities for intervention. Diabetes Metab Res Rev. 2022 Jul;38(5):e3536. doi: 10.1002/dmrr.3536
- Smith MJ, Cambier JC, Gottlieb PA. Endotypes in T1D: b lymphocytes and early onset. Curr Opin Endocrinol Diabetes Obes. 2020;27(4):225–230.
- Pozzilli P, Maddaloni E, Buzzetti R. Combination immunotherapies for type 1 diabetes mellitus. Nat Rev Endocrinol. 2015;11(5):289–297.